Skip to main content
SpringerLink
Log in

Myasthenia Gravis and Other Immune-Mediated Disorders of the Neuromuscular Junction

  • Chapter
  • First Online:
Neuroimmune Diseases

Part of the book series: Contemporary Clinical Neuroscience ((CCNE))

  • 1141 Accesses

Abstract

Myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS) and neuromyotonia represent the three autoantibody-mediated disorders at the neuromuscular junction. They give muscle weakness and fatigability as their dominating symptoms. The weakness has usually a preferred localization to some but not all muscles. MG subgroups reflect pathogenesis and direct therapy. Patients should always be classified according to type of antibody, thymus pathology, age at symptom onset and generalized versus pure ocular symptoms. LEMS and neuromyotonia are subgrouped according to paraneoplasia or not. All conditions have well-defined autoantibodies that bind in vivo and directly induce the muscle weakness. Therapy includes symptomatic drugs influencing the acetylcholine receptor activity in the postsynaptic membrane and immunosuppressive treatment influencing the pathogenic autoantibodies. This immunoactive treatment is not yet specific for the disease-inducing antigen-antibody interaction. Treatment is usually effective, and most patients obtain mild symptoms only or a full clinical remission. Comorbidities need to be treated, especially a thymoma in paraneoplastic MG or neuromyotonia and a lung cancer in paraneoplastic LEMS. Supportive therapy is important, and a well-adapted daily training program is recommended. Severe exacerbations (myasthenic crisis) with the need for respiratory support are rare, occur mainly together with infections, and need immediate intensive care.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Beeson D. Congenital myasthenic syndromes: recent advances. Curr Opin Neurol. 2016;29:565–71.

    CAS  PubMed  Google Scholar 

  2. Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375:2570–81.

    CAS  PubMed  Google Scholar 

  3. Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis – autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12:259–U291.

    CAS  PubMed  Google Scholar 

  4. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023–36.

    CAS  PubMed  Google Scholar 

  5. Titulaer MJ, Lang B, Verschuuren J. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10:1098–107.

    PubMed  Google Scholar 

  6. Lang B, Makuch M, Moloney T, et al. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. J Neurol Neurosurg Psychiatry. 2017;88:353–61.

    PubMed  Google Scholar 

  7. Hong Y, Zisimopoulou P, Trakas N, et al. Multiple antibody detection in ’seronegative’ myasthenia gravis patients. Eur J Neurol. 2017;24:844–50.

    CAS  PubMed  Google Scholar 

  8. Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE. EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21:687–93.

    CAS  PubMed  Google Scholar 

  9. Heldal AT, Owe JF, Gilhus NE, Romi F. SEROPOSITIVE MYASTHENIA GRAVIS: A NATIONWIDE EPIDEMIOLOGIC STUDY. Neurology. 2009;73:150–1.

    PubMed  Google Scholar 

  10. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10:46.

    PubMed  PubMed Central  Google Scholar 

  11. Hong Y, Skeie GO, Zisimopoulou P, et al. Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms. J Neurol. 2017;264:955–62.

    CAS  PubMed  Google Scholar 

  12. Pedersen EG, Hallas J, Hansen K, Jensen PEH, Gaist D. Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996-2009. Eur J Neurol. 2013;20:309–14.

    CAS  PubMed  Google Scholar 

  13. Guptill JT, Sanders DB, Evoli A. ANTI-MuSK Antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44:36–40.

    PubMed  Google Scholar 

  14. Hong Y, Li HF, Skeie GO, et al. Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients. J Neuroimmunol. 2016;298:51–7.

    CAS  PubMed  Google Scholar 

  15. Boldingh MI, Maniaol A, Brunborg C, et al. Prevalence and clinical aspects of immigrants with myasthenia gravis in northern europe. Muscle Nerve. 2017;55:819–27.

    PubMed  Google Scholar 

  16. Romi F, Hong Y, Gilhus NE. Pathophysiology and immunological profile of myasthenia gravis and its subgroups. Curr Opin Immunol. 2017;49:9–13.

    CAS  PubMed  Google Scholar 

  17. Wirtz PW, Nijnuis MG, Sotodeh M, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol. 2003;250:698–701.

    PubMed  Google Scholar 

  18. Titulaer MJ, Wirtz PW, Kuks JBM, et al. The Lambert-Eaton myasthenic syndrome 1988-2008: A clinical picture in 97 patients. J Neuroimmunol. 2008;201:153–8.

    PubMed  Google Scholar 

  19. Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumor Association Prediction Score Accurately Predicts Small-Cell Lung Cancer in the LEMS. J Clin Oncol. 2011;29:902–8.

    PubMed  Google Scholar 

  20. Vinge L, Andersen H. Muscle strength and fatigue in newly diagnosed patients with myasthenia gravis. Muscle Nerve. 2016;54:709–14.

    CAS  PubMed  Google Scholar 

  21. Andersen JB, Gilhus NE, Sanders DB. Factors affecting outcome in myasthenia gravis. Muscle Nerve. 2016;54:1041–9.

    CAS  PubMed  Google Scholar 

  22. Popperud TH, Boldingh MI, Rasmussen M, Kerty E. Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort. Eur J Paediatr Neurol. 2017;21:707–14.

    CAS  PubMed  Google Scholar 

  23. Antoine JC, Camdessanche JP. Paraneoplastic neuropathies. Curr Opin Neurol. 2017;30:513–20.

    CAS  PubMed  Google Scholar 

  24. Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 2014;52:139–45.

    CAS  PubMed  Google Scholar 

  25. Tsonis AI, Zisimopoulou P, Lazaridis K, et al. MuSK autoantibodies in myasthenia gravis detected by cell based assay - A multinational study. J Neuroimmunol. 2015;284:10–7.

    CAS  PubMed  Google Scholar 

  26. Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database of Syst Rev. 2011.

    Google Scholar 

  27. Kucukali CI, Kurtuncu M, Akcay HI, Tuzun E, Oge AE. Peripheral nerve hyperexcitability syndromes. Rev Neurosci. 2015;26:239–51.

    CAS  PubMed  Google Scholar 

  28. Maddison P. Neuromyotonia. Clin Neurophysiol. 2006;117:2118–27.

    PubMed  Google Scholar 

  29. Binks S, Vincent A, Palace J. Myasthenia gravis: a clinical-immunological update. J Neurol. 2016;263:826–34.

    CAS  PubMed  Google Scholar 

  30. Koneczny I, Stevens JAA, De Rosa A, et al. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. J Autoimmun. 2017;77:104–15.

    CAS  PubMed  Google Scholar 

  31. Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol. 2012;69:445–51.

    PubMed  Google Scholar 

  32. Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis - Reactivity and possible clinical significance. Arch Neurol. 2005;62:442–6.

    PubMed  Google Scholar 

  33. Skeie GO, Mygland A, Treves S, Gilhus NE, Aarli JA, Zorzato F. Ryanodine receptor antibodies in myasthenia gravis: Epitope mapping and effect on calcium release in vitro. Muscle Nerve. 2003;27:81–9.

    CAS  PubMed  Google Scholar 

  34. Gasperi C, Melms A, Schoser B, et al. Anti-agrin autoantibodies in myasthenia gravis. Neurology. 2014;82:1976–83.

    CAS  PubMed  Google Scholar 

  35. Suzuki S, Baba A, Kaida K, et al. Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies. Eur J Neurol. 2014;21:223–30.

    CAS  PubMed  Google Scholar 

  36. Romi F, Suzuki S, Suzuki N, Petzold A, Plant GT, Gilhus NE. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J Neurol. 2012;259:1312–6.

    CAS  PubMed  Google Scholar 

  37. Gilhus NE, Willcox N, Harcourt G, et al. Antigen presentation by thymoma epithelial-cells from myasthenia-gravis patients to potentially pathogenic t-cells. J Neuroimmunol. 1995;56:65–76.

    CAS  PubMed  Google Scholar 

  38. Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Strobel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev. 2013;12:875–84.

    CAS  PubMed  Google Scholar 

  39. Myking AO, Skeie GO, Varhaug JE, Andersen KS, Gilhus NE, Aarli JA. The histomorphology of the thymus in late onset, non-thymoma myasthenia gravis. Eur J Neurol. 1998;5:401–5.

    Google Scholar 

  40. Cavalcante P, Serafini B, Rosicarelli B, et al. Epstein-Barr Virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol. 2010;67:726–38.

    PubMed  Google Scholar 

  41. Gilhus NE. Myasthenia and the neuromuscular junction. Curr Opin Neurol. 2012;25:523–9.

    CAS  PubMed  Google Scholar 

  42. Avidan N, Le Panse R, Berrih-Aknin S, Miller A. Genetic basis of myasthenia gravis - A comprehensive review. J Autoimmun. 2014;52:146–53.

    CAS  PubMed  Google Scholar 

  43. Pirskanen R. Genetic aspects in myasthenia-gravis - family study of 264 finnish patients. Acta Neurol Scand. 1977;56:365–88.

    CAS  PubMed  Google Scholar 

  44. Salvado M, Canela M, Maria J, et al. Study of the prevalence of familial autoimmune myasthenia gravis in a Spanish cohort. J Neurol Sci. 2016;360:110–4.

    PubMed  Google Scholar 

  45. Lisak RP, Barcellos L. New Insights Into the Genetics of Autoimmune Myasthenia Gravis An Evolving Story. JAMA Neurol. 2015;72:386–7.

    PubMed  Google Scholar 

  46. Renton AE, Pliner HA, Provenzano C, et al. A Genome-Wide Association Study of Myasthenia Gravis. JAMA Neurol. 2015;72:396–404.

    PubMed  PubMed Central  Google Scholar 

  47. Bach JF. The etiology of autoimmune diseases: the case of myasthenia gravis. In: Wolfe GI, Meriggioli MN, Ciafaloni E, Ruff RL, editors. Myasthenia Gravis and Related Disorders I. Boston: Wiley Periodicals; 2012. p. 33–9.

    Google Scholar 

  48. Verschuuren J, Strijbos E, Vincent A. Neuromuscular junction disorders. Handbook of clinical neurology. Amsterdam: Elsevier; 2016;133:447–466..

    Google Scholar 

  49. Takamori M. Lambert-Eaton myasthenic syndrome: Search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis. J Neuroimmunol. 2008;201:145–52.

    PubMed  Google Scholar 

  50. Titulaer MJ, Verschuuren J. Lambert-Eaton myasthenic syndrome - Tumor versus nontumor forms. In: Kaminski HJ, Barohn RJ, editors. Myasthenia gravis and related disorders: 11th international conference; 2008. p. 129–34.

    Google Scholar 

  51. Fleisher J, Richie M, Price R, Scherer S, Dalmau J, Lancaster E. Acquired neuromyotonia heralding recurrent thymoma in myasthenia gravis. JAMA Neurol. 2013;70:1311–4.

    PubMed  PubMed Central  Google Scholar 

  52. Song J, Jing SS, Quan C, et al. Isaacs syndrome with CASPR2 antibody: A series of three cases. J Clin Neurosci. 2017;41:63–6.

    CAS  PubMed  Google Scholar 

  53. Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012;72:241–55.

    PubMed  Google Scholar 

  54. Heldal AT, Eide GE, Romi F, Owe JF, Gilhus NE. Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development. PLoS One. 2014;9:e114060.

    PubMed  PubMed Central  Google Scholar 

  55. Stergiou C, Lazaridis K, Zouvelou V, et al. Titin antibodies in "seronegative" myasthenia gravis - A new role for an old antigen. J Neuroimmunol. 2016;292:108–15.

    CAS  PubMed  Google Scholar 

  56. Priola AM, Priola SM, Giraudo MT, et al. Chemical-shift and diffusion-weighted magnetic resonance imaging of thymus in myasthenia gravis usefulness of quantitative assessment. Investig Radiol. 2015;50:228–38.

    Google Scholar 

  57. Priola AM, Priola SM, Gned D, Giraudo MT, Fornari A, Veltri A. Comparison of CT and chemical-shift MRI for differentiating thymoma from non-thymomatous conditions in myasthenia gravis: value of qualitative and quantitative assessment. Clin Radiol. 2016;71:E157–69.

    CAS  PubMed  Google Scholar 

  58. Gilhus NE, Nacu A, Andersen JB, Owe JF. Myasthenia gravis and risks for comorbidity. Eur J Neurol. 2015;22:17–23.

    CAS  PubMed  Google Scholar 

  59. Nacu A, Andersen JB, Lisnic V, Owe JF, Gilhus NE. Complicating autoimmune diseases in myasthenia gravis: a review. Autoimmunity. 2015;48:362–8.

    PubMed  PubMed Central  Google Scholar 

  60. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87:419–25.

    PubMed  PubMed Central  Google Scholar 

  61. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893–902.

    CAS  PubMed  Google Scholar 

  62. Iorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2015;262:1115–9.

    CAS  PubMed  Google Scholar 

  63. Randall KL. Rituximab in autoimmune diseases. Aust Prescr. 2016;39:131–4.

    PubMed  PubMed Central  Google Scholar 

  64. Sanders DB, McDermott M, Thornton C, et al. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71:394–9.

    CAS  Google Scholar 

  65. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71:400–6.

    CAS  PubMed  Google Scholar 

  66. Evoli A, Alboini PE, Damato V, et al. Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci. 2018;1412:82–9.

    CAS  PubMed  Google Scholar 

  67. Wolfe GIKH, Aban IB, Minisman G, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375:511–22.

    PubMed  PubMed Central  Google Scholar 

  68. Howard JF, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48:76–84.

    CAS  PubMed  Google Scholar 

  69. Gilhus NE. Eculizumab: a treatment option for mysthenia gravis? Lancet Neurol. 2017;16:947–8.

    PubMed  Google Scholar 

  70. Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database of Systematic Reviews. 2012.

    Google Scholar 

  71. Beecher G, Anderson D, Siddiqi ZA. Subcutaneous immunoglobulin in myasthenia gravis exacerbation A prospective, open-label trial. Neurology. 2017;89:1135–41.

    CAS  PubMed  Google Scholar 

  72. Kiessling P, Lledo-Garcia R, Watanabe S, et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study. Sci Transl Med. 2017;9:eaan1208.

    PubMed  Google Scholar 

  73. Rahbek MA, Mikkelsen EE, Overgaard K, Vinge L, Andersen H, Dalgas U. Exercise in myasthenia gravis: a feasibility study of aerobic and resistance training. Muscle Nerve. 2017;56:700–9.

    PubMed  Google Scholar 

  74. Andersen JB, Owe JF, Engeland A, Gilhus NE. Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study. Eur J Neurol. 2014;21:948–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol. 2007;14:38–43.

    CAS  PubMed  Google Scholar 

  76. Norwood F, Dhanjal M, Hill M, et al. Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group. J Neurol Neurosurg Psychiatry. 2014;85:538–43.

    PubMed  Google Scholar 

  77. Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis - Consequences for pregnancy, delivery, and the newborn. Neurology. 2003;61:1362–6.

    PubMed  Google Scholar 

  78. Hacohen Y, Jacobson LW, Byrne S, et al. Fetal acetylcholine receptor inactivation syndrome A myopathy due to maternal antibodies. Neurol Neuroimmunol Neuroinflammation. 2015;2:e57.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Medicine, University of Bergen, Bergen, Norway

    Nils Erik Gilhus

  2. Department of Neurology, Haukeland University Hospital, Bergen, Norway

    Nils Erik Gilhus

Authors
  1. Nils Erik Gilhus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nils Erik Gilhus .

Editor information

Editors and Affiliations

  1. Medical Education Promotion Center, Tokyo Medical University, Tokyo, Japan

    Hiroshi Mitoma

  2. Department of Neurology, CHU-Charleroi, Charleroi, Belgium, Department of Neurosciences, University of Mons, Mons, Belgium

    Mario Manto

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gilhus, N.E. (2019). Myasthenia Gravis and Other Immune-Mediated Disorders of the Neuromuscular Junction. In: Mitoma, H., Manto, M. (eds) Neuroimmune Diseases. Contemporary Clinical Neuroscience. Springer, Cham. https://doi.org/10.1007/978-3-030-19515-1_26

Download citation

Publish with us

Policies and ethics

Search

Navigation